Dr Noor Alwash

Consultant Dermatologist

MBBS, MRCP (UK), MRCP (Dermatology)

General Medical Council Number: 7007302

I graduated from medical school in 2007 and decided early in my career to specialise in Dermatology. I finished my dermatology training at the Brighton and Sussex University Hospitals Trust and obtained my MRCP in dermatology from the Royal College of Physicians in 2018.

In 2020 I was appointed as a consultant dermatologist at the East Sussex Healthcare NHS trust.

I’m joint clinical lead of the dermatology department at the East Sussex Healthcare NHS trust, the lead of biological treatment and lead of phototherapy.

I have a special interest in medical dermatology (acne, eczema, psoriasis and other inflammatory skin conditions) and skin cancer. In addition I have an interest in aesthetic dermatology.

Clinic Times

Thursday (evenings)

Friday’s

Treatment information

Some of the principal treatments carried out by Dr Noor Alwash include:

Dermatology

Additional information

MBBS / University of Jordan / 2007
Bachelor of Medicine, Bachelor of Surgery
British Association of Dermatologists

I have been involved in several research studies in dermatology including:

Heads UP study. A phase 3, randomized, multi-center study that will evaluate upadacitinib versus dupilumab in adults (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. The study is comprised of a 35-day screening period, a 24-week blinded treatment period, and a 12-week follow-up period.

ALLEGRO study. A global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss.

PROSE study (secukinumab in patients with severe chronic plaque psoriasis)

LEO study: Secukinumab In patients with moderate to severe active, chronic plaque psoriasis who have failed on TNFa antaGoNists: A clinical Trial Eval Uating Treatment Results (SIGNATURE)

A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis.

Our first year experience in tele-dermatology. Presented as a poster presentation at the BAD annual meeting in July 2019. Abstract was published in the BJD.

A survey of the dermatological knowledge of tattoo artists. Presented as a poster at the BAD annual meeting in July 2019. Abstract was published in the BJD.

Extreme lip swelling caused by orofacial granulomatosis in two children and a novel and well tolerated treatment. Presented as a poster at the ESPD annual meeting in May 2019.

Consent forms for systemic and biologic therapy. Presented as a poster at the EADV annual meeting in 2018.

The Virtual Systemic Monitoring Clinic. Was presented as an oral presentation at the BAD annual meeting in July 2018. Abstract was published in the BJD.

A case of complete loss of all fingernails following application of gel nail polish. Presented as a poster at the BAD annual meeting in July 2018. Abstract was published in the BJD.

The use of the Therma probe biosensor in aiding the assessment and management of skin lesions. Presented as a poster at the BAD annual meeting in July 2018. Abstract was published in the BJD.

A case of unilateral rash in a 13 year old girl. Presented as a poster at the ESPD annual meeting in June 20.

Consultant Dermatologist, East Sussex Healthcare NHS Trust

Joint clinical lead of the dermatology department at the East Sussex Healthcare NHS trust.

The lead of biological treatment and lead of phototherapy at East Sussex Healthcare Trust

Private secretary: Sarah

Private secretary telephone: 07933 644944

Private secretary email: sussexdermatology@gmail.com

How can we help you?

Interested in finding out more?

Speak to a member of our team

Phone01424 757400

Enquiry form

DD slash MM slash YYYY

Marketing Information
Sussex Premier Health would like to provide you with marketing information about products and services offered by Sussex Premier Health and by selected third-party partners. If you do not consent for us to process your personal data for marketing activities, we will still be able to contact you about your enquiry.
Please tick the box(es) to confirm your consent to receive marketing information from Sussex Premier Health:

Section Break

Marketing

We may contact you by email, SMS or phone about your enquiry. If we try to contact you by phone (mobile and/or landline) and you are not available, we may leave you a voicemail message. We may also use your details to contact you about patient surveys we use for improving our service or monitoring outcomes, which are not a form of marketing.

Section Break